Barclays initiated coverage of Protagonist Therapeutics (PTGX) with an Overweight rating and $72 price target Protagonist is leveraging its peptide technology platform to address hematology, immunology and metabolic disorders, and the firm expects shares to continue to appreciate on regulatory milestones in 2026 and clinical de-risking of its pipeline over the next 12 months, with important catalysts across its pipeline, the analyst tells investors in a research note. Protagonist’s oral peptide platform has also received initial validation with the clinical success in psoriasis with JNJ-2113, the firm added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics initiated with an Overweight at Barclays
- Protagonist Therapeutics: Promising Phase 2b Results and Strong Safety Profile Justify Buy Rating
- Protagonist Therapeutics: Buy Rating Backed by Promising Drug Assets and Strategic Partnerships
- Protagonist Therapeutics initiated with an Outperform at Leerink
- Protagonist Therapeutics announces icotrokinra application submitted to EMA